Welcome to our dedicated page for Aclaris Therapeutics SEC filings (Ticker: ACRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aclaris Therapeutics, Inc. (ACRS) SEC filings page on Stock Titan provides access to the company’s public filings with the U.S. Securities and Exchange Commission, including current reports on Form 8-K and other key documents referenced in its investor communications. Aclaris is a Delaware-incorporated, Nasdaq-listed clinical-stage biopharmaceutical company, and its common stock is registered under Section 12(b) of the Securities Exchange Act of 1934.
For ACRS, SEC filings are an important source of information on financial results, clinical development progress, and corporate presentations. Recent Forms 8-K have furnished press releases announcing quarterly and year-to-date financial results, described as including revenue from contract research and licensing, research and development expenses tied to product candidates such as bosakitug, ATI-052 and ATI-2138, and general and administrative costs. Other 8-K filings have furnished R&D Day and corporate overview presentations and detailed top line results from the Phase 2a trial of ATI-2138 in atopic dermatitis.
Through this page, users can locate Aclaris’ current reports that summarize material events, such as updates to its clinical pipeline, conference calls discussing top line clinical data, and investor presentations. While the examples provided are 8-K filings, the SEC Filings page is also the natural place to look for Aclaris’ annual reports on Form 10-K, quarterly reports on Form 10-Q, and any proxy statements or registration statements the company files, which together outline its risk factors, business description, and governance structure.
Stock Titan enhances these filings with AI-powered tools that can help explain complex financial and scientific disclosures in plain language. For ACRS, this can be particularly useful when reviewing detailed discussions of its immuno-inflammatory pipeline, revenue components such as licensing and contract research, and non-cash items like royalty income and contingent consideration revaluations. The page also provides a path to monitor any future insider transaction reports on Form 4 or other ownership-related filings that may be associated with Aclaris’ executive officers and directors.
Aclaris Therapeutics ownership disclosure: RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky and Rajeev Shah report beneficial interests in 7,626,705 shares of Aclaris common stock, representing 6.3% of the class based on 120,595,189 shares outstanding as of January 30, 2026. The filing states the Fund directly holds the 7,626,705 shares; RA Capital serves as investment adviser with shared voting and dispositive power over those shares. The Reporting Persons disclaim status as a group and include a statement that the Fund has delegated voting and disposition authority with a 61-day notice constraint.
Aclaris Therapeutics Inc receives an amended beneficial ownership filing from The Vanguard Group reporting 0 shares of Common Stock and 0% ownership in this amendment. The filing notes an internal realignment at Vanguard on January 12, 2026 that led certain subsidiaries and divisions to report separately under SEC Release No. 34-39538.
The filing is administrative: it states Vanguard and its covered accounts hold no beneficial shares of Aclaris Common Stock as reported and documents the change in reporting allocation among Vanguard entities. The signature block records filing execution by Ashley Grim, Head of Global Fund Administration.
Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd. and David Kroin report beneficial ownership of 9,345,000 shares of Aclaris Therapeutics common stock, representing 7.01% of the class as of March 16, 2026. The filing states the holders have shared voting and dispositive power over 9,345,000 shares and zero sole voting or dispositive power.
The filing explains the percent is calculated using 133,295,189 shares, derived from 120,595,189 shares outstanding as of January 30, 2026 plus 12.7 million shares sold under a sales agreement from March 2, 2026 through March 9, 2026. The report is a joint Schedule 13G filing under Rule 13d-1(k) and lists Deep Track Capital, LP as the relevant entity for control purposes.
Aclaris Therapeutics reported that on March 10, 2026 it sold 5.7 million shares of its common stock, generating $20.0 million in aggregate gross proceeds. The sale was made under its amended and restated sales agreement with Leerink Partners LLC and Cantor Fitzgerald & Co.
The agents informed the company that the shares were purchased by Frazier Life Sciences, Kalehua Capital and Adage Capital Partners LP. The disclosure is furnished under Regulation FD and is not treated as filed for liability purposes under the Exchange Act.
Aclaris Therapeutics, Inc. reported that from March 2–9, 2026 it sold 12.7 million shares of its common stock through its amended and restated sales agreement with Leerink Partners LLC and Cantor Fitzgerald & Co.
These sales generated aggregate gross proceeds of $39.8 million and the shares were purchased by institutional investors, including Deep Track Capital. The disclosure is provided under Regulation FD and is expressly not deemed filed for liability purposes under Section 18 of the Exchange Act.
Aclaris Therapeutics Chief Financial Officer Kevin Balthaser reported equity compensation-related transactions on March 1, 2026. He exercised 2,375 Restricted Stock Units, which converted into 2,375 shares of common stock at a price of $0.0000 per share. Each restricted stock unit represents a contingent right to receive one share of common stock of the company.
To cover tax withholding obligations tied to the vesting and settlement of these units, 677 shares of common stock were withheld and disposed of at $2.87 per share, as indicated by transaction code F for tax-withholding disposition. After these transactions, Balthaser directly owned 187,453 shares of common stock.
Aclaris Therapeutics files its annual report describing a broad immuno-inflammatory pipeline and ongoing operating losses. The company is developing bosakitug and ATI-052 (anti-TSLP–based antibodies) plus oral ITK/JAK3 and ITK inhibitors for atopic dermatitis, asthma and other T cell–mediated diseases, alongside earlier-stage KINect discovery programs.
Aclaris reported net losses of $64.9 million in 2025 and $132.1 million in 2024, with an accumulated deficit of $967.8 million, funded mainly through equity and non-dilutive financing. Cash, cash equivalents and marketable securities totaled $151.4 million as of December 31, 2025, which management believes will fund operations for more than 12 months.
Aclaris Therapeutics reported fourth quarter and full-year 2025 results and highlighted progress across its immuno-inflammatory pipeline. Net loss narrowed to $19.8 million in Q4 2025 from $96.6 million a year earlier, and to $64.9 million for 2025 from $132.1 million in 2024.
Total revenue was $1.3 million in Q4 2025 and $7.8 million for the year, reflecting lower licensing revenue after a 2024 milestone. R&D expenses rose to $52.6 million in 2025 as the company advanced bosakitug, ATI-052 and ATI-9494.
Cash, cash equivalents and marketable securities were $151.4 million as of December 31, 2025. Aclaris expects this to fund operations into the second half of 2028. The company reported positive interim Phase 1a data for ATI-052, initiated Phase 1b trials in atopic dermatitis and asthma, and plans a Phase 2 bosakitug readout and an IND filing for ATI-9494 in 2026.
Aclaris Therapeutics, Inc. received an updated ownership report showing that BML Investment Partners, L.P. beneficially owns 14,250,000 shares of its common stock, representing 11.9% of the class as of 12/31/2025.
BML reports shared power to vote and dispose of all these shares, with no sole voting or dispositive power. The filing states the securities were not acquired or held for the purpose of changing or influencing control of Aclaris.
Aclaris Therapeutics CEO and director Walker Neal reported new equity awards granted on February 2, 2026. He received 274,800 restricted stock units, each representing the right to receive one share of common stock, and an employee stock option covering 961,700 shares of common stock.
The restricted stock units vest in four equal installments on the first, second, third, and fourth anniversaries of February 2, 2026, contingent on his continued service. The stock option, with a $3.61 exercise price per share, is exercisable as it vests over the same four-year schedule, also subject to continuous service.